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Abstract: PURPOSE Mesothelioma of the tunica vaginalis testis (MTVT) is a rare tumor, and currently,
there are no published treatment recommendations. METHODS We performed a systematic literature re-
view and synthesized clinical presentation, clinicopathological factors associated with metastatic disease,
treatment options, and outcomes in men with MTVT. RESULTS We included 170 publications providing
data on 275 patients. Metastatic disease occurred in 84/275 (31%) men with malignant MTVT: Most
common sites included retroperitoneal lymph nodes (LNs) (40/84, 48%), lungs (30/84, 36%), and inguinal
LNs (23/84, 27%). Invasion of the spermatic cord or scrotum was the only risk factor for local recurrence
[odds ratio (OR) 3.21, 95% confidence interval (CI) 1.36-7.57]. Metastatic disease was associated with
age ฀ 42 years (OR 3.02, 95% CI 1.33-6.86), tumor size ฀ 49 mm (OR 6.17, 95% CI 1.84-20.74), presence
of necrosis (OR 8.31, 95% CI 1.58-43.62), high mitotic index (OR 13.36, 95% CI 1.53-116.51) or angi-
olymphatic invasion (OR 3.75, 95% CI 1.02-13.80), and local recurrence (OR 4.35, 95% CI 2.00-9.44).
Complete remission in the metastatic setting was observed in five patients, most of whom were treated
with multimodal therapy. Median survival in patients with metastatic disease was 18 months (IQR 7-
43). CONCLUSION Malignant MTVT is a rare but aggressive disease. Since local recurrence is a risk
factor for metastatic progression, we recommend aggressive local treatment. Survival and response to
any treatment in the metastatic setting are limited.
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Abstract
Purpose Mesothelioma of the tunica vaginalis testis (MTVT) is a rare tumor, and currently, there are no published treatment 
recommendations.
Methods We performed a systematic literature review and synthesized clinical presentation, clinicopathological factors 
associated with metastatic disease, treatment options, and outcomes in men with MTVT.
Results We included 170 publications providing data on 275 patients. Metastatic disease occurred in 84/275 (31%) men 
with malignant MTVT: Most common sites included retroperitoneal lymph nodes (LNs) (40/84, 48%), lungs (30/84, 36%), 
and inguinal LNs (23/84, 27%).
Invasion of the spermatic cord or scrotum was the only risk factor for local recurrence [odds ratio (OR) 3.21, 95% confi-
dence interval (CI) 1.36–7.57]. Metastatic disease was associated with age ≥ 42 years (OR 3.02, 95% CI 1.33–6.86), tumor 
size ≥ 49 mm (OR 6.17, 95% CI 1.84–20.74), presence of necrosis (OR 8.31, 95% CI 1.58–43.62), high mitotic index (OR 
13.36, 95% CI 1.53–116.51) or angiolymphatic invasion (OR 3.75, 95% CI 1.02–13.80), and local recurrence (OR 4.35, 95% 
CI 2.00–9.44). Complete remission in the metastatic setting was observed in five patients, most of whom were treated with 
multimodal therapy. Median survival in patients with metastatic disease was 18 months (IQR 7–43).
Conclusion Malignant MTVT is a rare but aggressive disease. Since local recurrence is a risk factor for metastatic progres-
sion, we recommend aggressive local treatment. Survival and response to any treatment in the metastatic setting are limited.
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Introduction
Mesothelioma typically involves the pleura or peritoneum 
and only rarely the tunica vaginalis testis (Gurdal and 
Erol 2001; Plas et al. 1998a). Due to the low prevalence 
of mesothelioma of the tunica vaginalis testis (MTVT), 
treatment recommendations have not been developed. We 
collated published case reports of men with MTVT to 
describe clinicopathological factors associated with local 




Data acquisition and search strategy
A systematic literature review was performed using the 
Preferred Reporting Items for Systematic Reviews and 
Meta-analysis (PRISMA) statement (Moher et al. 2009, 
2015). Prior to data acquisition, the study protocol/search 
strategy was published on the PROSPERO registry (http://
www.crd.york.ac.uk/PROSP ERO; Registration Number 
CRD42019129595).
Our search identified articles published up to 14th Janu-
ary 2019 and utilised the following electronic databases: 
 MEDLINE®,  Embase®,  Scopus®, the Cochrane Database 
of Systematic Reviews, and Web of Science. To identify 
all relevant articles, a clinical medical librarian applied 
a broad approach using several combinations, synonyms 
and related search terms to “para-/intra-/testicular meso-
thelioma”, “epididymal mesothelioma”, or “para-/intra-/
testicular mesenchymal tumor/neoplasm”. Non-English 
literature was excluded unless the abstract was available 
in English or the full text in French, Spanish, Italian, Por-
tuguese, or German. Moreover, the reference lists of the 
identified publications were screened manually to identify 
additional studies. For the search strategy, see Supplemen-
tary File 1. After deduplication, two authors (JBG, JNF) 
screened the titles and abstracts independently and data 
from the same study that appeared in multiple publications 
were included only once. Finally, disagreements were dis-
cussed and resolved by consensus or by third-party arbitra-
tion (CDF).
Types of outcome measures included and data extraction
Studies containing data on patient characteristics, clin-
icopathological features, treatment of local or metastatic 
disease, site of metastases, and follow-up information were 
eligible for this review. The data extraction sheet was devel-
oped according to the Cochrane Consumers and Communi-
cation Review Group’s data extraction template. Whenever 
possible, data were gathered at the single-patient-level.
Statistical analysis
Categorical variables are presented as percentages and 
were compared using the Chi-square test of independence. 
The assessment of normality for continuous variables was 
performed visually and using the Shapiro–Wilk test. The 
results for normally distributed variables are expressed as 
mean ± standard deviation (SD), while non-normally dis-
tributed variables are presented as median and interquartile 
ranges (IQRs). The independent samples t test was used for 
normally distributed data and the Mann–Whitney U test 
for variables with non-normally distributed data. Weighted 
medians were used to estimate previously processed statis-
tical data from cohort studies as well as individual patient 
data from single-case reports. The optimal cut-off value 
for continuous variables was determined using receiver-
operating curve (ROC) analyses and the maximal Youden’s 
index (= Sensitivity + Specificity– 1) (Youden 1950). All p 
values < 0.05 were considered statistically significant; all 
statistical tests were two-sided.
Results
Included studies
After deduplication and title as well as abstract screening, 
194 of the originally identified 8,188 publications were eli-
gible for full-text review (Fig. 1). We finally included 170 
studies, resulting in a dataset of 275 patients, consisting of 
140 single-case reports and 30 case series.
Subgroups and location, demographics, clinical 
symptoms, and laboratory findings
We identified 275 cases of MTVT, of which 227/275 
(83%) were classified as “malignant mesothelioma”, with 
a histopathological sub-classification including epithelioid 
(130/227, 57%), sarcomatoid (4/227, 2%), and biphasic 
subtype (53/227, 23%) and malignant mesothelioma of an 
unknown subtype (40/227, 18%). Other histologies included 
well-differentiated papillary mesothelioma (30/275, 11%) 
and mesothelioma of uncertain malignant potential (13/275, 
5%). Cases of benign cystic mesotheliomas (5/275, 2%), 
also known as multilocular inclusion cysts, which typically 
develop in the peritoneum, were also included (Table 1). 
The median age at diagnosis was 62 years (IQR 44–73). The 
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tumor invaded the tunica vaginalis as the only affected struc-
ture in 170/275 patients (62%); for the remaining patients, 
the tunica vaginalis plus other (multiple) structures were 
involved: tunica albuginea and/or testis in 55/275 (20%); 
epididymis in 34/275 (12%), spermatic cord in 65/275 
(24%), and the scrotum (tunica dartos and dermis) in 20/275 
(7%).
Clinical presentation
Data regarding clinical presentation were available for 
259/275 patients (94%) (Table 1). Most patients presented 
with a painless testicular mass/swelling, or a hydrocele 
(244/259, 94%). Scrotal pain was described in 40/259 cases 
(15%), and inflammation with orchitis or epididymitis in 
13/259 (5%). Incidental findings during scrotal surgery rep-
resented 93/275 cases (36%). We found no reports suggest-
ing hormonal changes leading to gynecomastia or earlier/
later puberty. Of the 154 patients with information about 
potential environmental risk factors of mesothelioma, 59 
(38%) described exposure to asbestos, while smoking was 
mentioned by 11 patients (4%). Of the 52 patients with spe-
cific information on testicular tumor markers, lactate dehy-
drogenase (LDH) was elevated in 3/52 cases (6%), human 
chorionic gonadotropin (HCG) in 2/52 cases (4%), and 
alpha-fetoprotein (AFP) in 1/52 cases (2%).
Local treatment and recurrence
Most patients (170/275, 62%) underwent radical inguinal 
orchiectomy as the primary local treatment, while testis-
sparing surgery (TSS) was performed in 52/275 cases (19%). 
Primary hemiscrotectomy was reported in 28/275 (10%), 
transscrotal orchiectomy in two (< 1%), hydrocelectomy as 
the only surgical intervention in eight (3%), and fine nee-
dle aspiration (FNA) as the diagnostic procedure without 
any further treatment in three (1%). After primary TSS, 
secondary completion orchiectomy and secondary comple-
tion hemiscrotectomy were performed in 13 (25%) and 6 
patients (12%), respectively. After primary orchiectomy, 
secondary hemiscrotectomy was performed in three (6%) 
patients. In 12 (4%), the primary therapy was not reported. 
Of the 203 patients with available follow-up data, 117 (58%) 
displayed no evidence of disease after a median of 19 (IQR 
9–41) months. By contrast, 67 (33%) died after a median of 
20 months (IQR 7–48). 19 men (9%) were alive with disease 
after a median of 21 months (IQR 8–24). Local recurrence 
was observed in 35/275 patients (13%) (Supplementary 
Table 1). Of the 32 patients for whom follow-up time was 
available, the median time from diagnosis to local recurrence 
was 17 months (IQR 4–24 months). The following recur-
rence rates were reported for the different primary treatment 
options: radical inguinal orchiectomy: 24/170 (14%) after a 
Fig. 1  Flowchart of the study selection process
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Table 1  Patient characteristics 
overall and on individual 
patient-level data




Number of patients 221 (= 100%) 275 (= 100%)
Histopathological (sub-)types
 Malignant MTVT (%) 180/221 (81%) 227/275 (83%)
 Epithelioid type (% of malign. MTVT) 100/180 (56%) 130/227 (57%)
 Sarcomatoid type (% of malign. MTVT) 4/180 (2%) 4/227 (2%)
 Biphasic type (% of malign. MTVT) 40/180 (22%) 53/227 (23%)
 Malignant MTVT of unknown subtype (% of malign. 
MTVT)
36/180 (20%) 40/227 (18%)
 Mesothelioma of uncertain malig. potential (%) 13/221 (6%) 13/275 (5%)
 Well differentiated papillary MTVT (%) 23/221 (10%) 30/275 (11%)
 Benign cystic mesothelioma (%) 5/221 (2%) 5/275 (2%)
 Missing (%) 0/221 (0%) 0/221 (0%)
Age (years)
 Median (IQR) 62 (44–73) –
 Missing (%) 1/221 (< 1%)
Side
 Left (%) 105/221 (48%) 127/275 (46%)
 Right (%) 98/221 (44%) 107/275 (39%)
Bilateral (%) 5/221 (2%) 5/275 (2%)
Missing (%) 13/221 (6%) 36/275 (13%)
Clinical presentation 209/221 (95%) 259/275 (94%)
 Testicular enlargement/swelling/mass (%) 200/209 (96%) 244/259 (94%)
Scrotal pain/discomfort (%) 40/209 (19%) 40/259 (15%)
Epididymitis/orchitis (%) 13/209 (6%) 13/259 (5%)
Lymphadenopathy (%) 7/209 (3%) 7/259 (3%)
Incidental finding during scrotal surgery (%) 87/209 (42%) 93/259 (36%)
Missing (%) 12/221 (5%) 16/275 (6%)
Exposition
 Asbestos (%) 146/221 (66%) 154/275 (56%)
 Yes (%) 51/146 (35%) 59/154 (38%)
 No (%) 95/146 (65%) 95/154 (62%)
 Smoking (%) 11/221 (5%) 11/275 (4%)
 Mean pack years (SD) 21 (± 13) –
 Median pack years (IQR) 23 (12–29) –
 Missing (%) 74/221 (33%) 121/275 (44%)
Tumor markers
 AFP elevated (%) 1/52 (2%) 1/52 (2%)
 HCG elevated (%) 2/52 (4%) 2/52 (4%)
 LDH elevated (%) 3/52 (6%) 3/52 (6%)
 Missing (%) 168/221 (76%) 168/275 (61%)
Local primary treatment
 Radical inguinal orchiectomy (%) 136/221 (62%) 170/275 (62%)
 Testis-sparing surgery (%) 41/221 (19%) 52/275 (19%)
 Radical hemiscrotectomy (%) 26/221 (12%) 28/275 (10%)
 Hydrocelectomy only (%) 8/221 (4%) 8/275 (3%)
 Fine needle aspiration only (%) 3/221 (1%) 3/275 (1%)
 Transscrotal orchiectomy (%) 2/221 (< 1%) 2/275 (< 1%)
 Missing (%) 5/221 (2%) 12/275 (4%)
Local secondary treatment
 Orchiectomy after TSS (% of TSS) 13/41 (32%) 13/52 (25%)
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median of 10 months (IQR 3–24), TSS: 6/52 (12%) after a 
median of 24 months (IQR 7–30), and radical hemiscrotec-
tomy: 3/28 (11%) after a median of 24 months (IQR 19–55). 
Local recurrence in benign multicystic mesothelioma or 
MTVT of uncertain malignant potential was observed in 
one case after TSS and transscrotal orchiectomy, respec-
tively. Salvage treatment was successful in seven patients 
and included local resection of recurrence and orchiectomy 
in five and two men with MTVT, respectively. In univariable 
regression analyses, only invasion of the spermatic cord or 
scrotum was associated with local recurrence (OR 3.21, 95% 
CI 1.36–7.57, p = 0.008) (Table 2).
Adjuvant therapy
Lymph-node dissection (LND) was performed in 21 men 
of whom 12 had inguinal LND, 8 retroperitoneal LND, 7 
pelvic LND, and 6 LND in multiple locations. In 5 of the 
21 patients (24%), histological analysis showed lymph-node 
metastases (LNs), one without recurrence during follow-
up. Two patients were alive with disease (one with ongoing 
chemotherapy and one with no further therapeutic interven-
tions). Two patients died from metastatic spread after pallia-
tive radiotherapy and radiochemotherapy, respectively. An 
additional three patients without positive lymphadenectomy 
results displayed evidence of distant recurrence during fol-
low-up. Thus, 6 of the 21 patients (29%) developed systemic 
disease despite adjuvant LND. Local and/or metastatic 
relapse after adjuvant chemotherapy or chemoradiotherapy 
was observed in 5/9 (56%) patients. Used chemotherapy 
agents included Doxorubicin, Carboplatin, or combina-
tion therapy with Adriamycin plus Cyclophosphamide or 
Paclitaxel, and the radiation field included the retroperito-
neal and pelvic lymph nodes and pelvic region. 6/11 (55%) 
men relapsed after several radiotherapy protocols including 
radiation of the scrotum as well as the retroperitoneal and 
inguinal LNs with maximum doses between 55 and 60.5 Gy.
Onset and site of metastasis
Overall, metastatic disease was observed in 84/275 patients 
(31%). The following sites of metastasis were described: 
Retroperitoneal lymph nodes (RPLNs) (40/84, 48%); lungs 
(30/84, 36%); inguinal LNs (23/84, 27%); peritoneal sur-
faces (18/84, 21%); pleura (10/84, 12%); skin (10/84, 12%); 
liver (8/84, 10%); pelvic LNs, mediastinal LNs and bones 
(each 7/84, 8%); supraclavicular LNs (5/84, 6%); abdominal 
LNs (4/84, 5%); brain, kidneys, bladder, or pancreas (each 
2/84, 2%), colon, rectum, spleen, and cervical LNs (each 
1/84, 1%) (Fig. 2). Regarding the subgroup of 29/84 patients 
(35%) with only one metastatic site, the RPLNs (7/29, 24%) 
and lungs (7/29, 24%) were the most common primary sites. 
Other solitary metastatic sites included the peritoneum 
(4/29, 14%), inguinal LNs, and bones (3/29, 10% each). Two 




 Hemiscrotectomy after TSS (% of TSS) 6/41 (15%) 6/52 (12%)
 Hemiscrotectomy after Orchiectomy (% of RIO) 3/41 (7%) 3/52 (6%)
Histopathology features
Necrosis (%) 27/221 (12%) 31/275 (11%)
Angiolymphatic invasion (%) 33/221 (15%) 40/275 (15%)
Mitotic activity (%) 53/221 (24%) 59/275 (21%)
High mitotic activity (> 3/10 HPF) (%) 26/221 (12%) 32/275 (12%)
Missing (%) 143/221 (65%) 174/275 (63%)
Size (mm)
 Median of all histologies (IQR) 35 (15–70) –
 Malignant MTVT (IQR) 40 (15–80)
 Epithelioid type (IQR) 38 (14–100)
 Biphasic type (IQR) 55 (27–100)
 Well-differentiated papillary MTVT (IQR) 15 (10–29)
 Radical inguinal orchiectomy (IQR) 38 (13–78) –
 Testis-sparing surgery (IQR) 24 (12–63) –
 Radical hemiscrotectomy (IQR) 40 (30–150) –
 Missing (%) 148/221 (67%)
MTVT mesothelioma of the Tunica Vaginalis Testis, RIO radical inguinal orchiectomy, TSS testis-sparing 
surgery, AFP alpha-fetoprotein, HCG human chorionic gonadotropin, LDH lactate dehydrogenase, IQR 
inter quartile range
*This column includes only patients of which individual patient-level data was available
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case reports each (2/29, 7%) described singular metastasis of 
MTVTs to the brain, the liver, and the mediastinal LNs. The 
exact timing of metastatic disease in relation to diagnosis 
was described in 52/84 (62%) patients. Metastatic disease at 
initial diagnosis was described in 18/52 men (35%), whereas 
34/52 men (65%) presented with metastatic recurrence dur-
ing a median follow-up of 17 months (IQR 10–29).
Risk factors for metastatic disease
Patients with well-differentiated papillary mesothelioma or 
benign multicystic mesothelioma did not develop metastatic 
disease. Regarding the different histologic sub-classifications 
of malignant MTVT on individual patient-level data, 34/100 
patients (34%) with epithelioid type and 18/40 (45%) with 
biphasic type exhibited metastatic behaviour. The remaining 
patients with metastatic disease were either unclassified or 
belonged to other rare subtypes of malignant MTVT [15/36 
(42%) malignant MTVT without subtype information, 1/13 
(8%) MTVT of uncertain malignant potential].
Individual patient-level data to analyse further risk factors 
were available for 68 men with metastatic MTVT. Risk fac-
tors for metastasis included age ≥ 42 years (OR 3.02, 95% CI 
1.33–6.86, p = 0.009), tumor size ≥ 49 mm (OR 6.17, 95% CI 
1.84–20.74, p = 0.003), and presence of necrosis (OR 8.31, 
95% CI 1.58–43.62, p = 0.012), high mitotic index (OR 
13.36, 95% CI 1.53–116.51, p = 0.019), or angiolymphatic 
invasion (OR 3.75, 95% CI 1.02–13.80, p = 0.047), and local 
recurrence (OR 4.35, 95% CI 2.00–9.44, p < 0.001).
Treatment and outcome in men with metastatic 
disease
During a median follow-up of 18  months (IQR 7–43), 
55/84 metastatic MTVT patients (65%) died, and 13/84 
(15%) were alive with disease, while 11 patients were 
either lost to follow-up or without information on survival. 
Complete remission in the metastatic setting was reported 
in five men (Supplementary Table 2): the first patient (#7) 
with an epithelial MTVT was treated with an orchiectomy 
and RPLND showing involvement of one retroperitoneal 
lymph node. Data about staging CT at diagnosis as well as 
information about further treatment during follow-up were 
not available. This patient remained free of disease for at 
least 66 months (Bertolotto et al. 2016). The second patient 
(#12) with an epithelioid MTVT developed mediastinal LN 
metastases 36 months after primary radical orchidectomy. 
After six cycles of Cisplatin and Pemetrexed and mainte-
nance with Pemetrexed, there was no evidence of disease 
after 42 months of follow-up (Doris et al. 2015). The third 
patient (#35), with a malignant MTVT of unknown histo-
logical subtype and peritoneal metastases at initial staging, 
was treated with testis-sparing surgery, peritonectomy, and 
Table 2  Univariable regression analyses for local recurrence and metastatic disease
OR odds ratio, CI confidence interval, MTVT mesothelioma of the tunica vaginalis testis, TSS testis-sparing surgery
*Cases with individual patient-level data
Variable Local recurrence Metastatic disease
# With available 
variable (% of 221*)
OR CI p value OR CI p-value
Age (≥ 42 years) 211 (95) 2.47 0.82–7.42 0.107 3.02 1.33–6.86 0.009





































Necrosis 45 (20) 1.13 0.22–5.79 0.880 8.31 1.58–43.62 0.012
High mitotic index 43 (19) 6.26 0.70–56.29 0.101 13.36 1.53–116.51 0.019
Angiolymphatic invasion 50 (23) 1.26 0.20–7.64 0.802 3.75 1.02–13.80 0.047
Location/involvement
Tunica vaginalis only
Invasion of tunica albuginea
and/or testis
Invasion of epididymis































 Recurrence versus no recurrence 209 (95) – – – 4.35 2.00–9.44  < 0.001
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intraperitoneal hyperthermic perfusion chemotherapy. He 
remained free of disease after a follow-up of 18 months 
(Schure et al. 2006). The fourth patient (#42), who had 
epithelioid MTVT with extension to the spermatic cord in 
the inguinal canal and metastatic spread within the pelvis 
and the abdomen, was initially treated with hemiscrotec-
tomy with resection of the inguinal mass and abdominal 
cytoreductive surgery with extensive stripping all perito-
neal surfaces followed by intra-operative, intra-peritoneal 
chemotherapy using Cisplatin and Doxorubicin. This patient 
was recurrence-free survival at 5 years (Sebbag et al. 2001). 
The fifth patient (#60), with epithelioid MTVT invading the 
tunica albuginea, the spermatic cord and external scrotal 
layers, was treated with a primary hemiscrotectomy. After 
resection of visible metastases in the retroperitoneum, six 
cycles of chemotherapy with Adriamycin and Cyclophos-
phamide and radiation therapy of 25 Gy over 3 weeks, the 
patient was disease-free at 36 months (Lopez et al. 1995). 
Of metastatic cases with available follow-up, 20 out of 21 
(95%) patients treated with surgery only and 64 out of 68 
(94%) patients treated with multimodal therapies progressed.
Fig. 2  Anatomical locations of metastatic sites at initial staging and during follow-up. Affected organs are listed on the left and lymph-node 
locations on the right
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Discussion
Our analysis of published case series is the largest and most 
comprehensive summary of the available literature regarding 
MTVT. It also extends the previous reviews (Bisceglia et al. 
2010; Plas et al. 1998b; Vimercati et al. 2019; Zhang and 
Goldsztajn 2019), and therefore, several important insights 
can be discussed.
The highest incidence was found in men in their sixties; 
however, there is a wide age range, even patients under 
20 years can be affected. MTVT usually presents as a tes-
ticular mass or is incidentally discovered during or after 
inguino-scrotal surgery. Therefore, the primary local treat-
ment depends on the clinical scenario, but treatment should 
also be planned in the knowledge that MTVT can show mul-
tifocal growth and that local recurrence might be associated 
with metastatic disease.
In men with first presentation, several recommendations 
might help to guide clinicians in decision-making, but those 
are based on very limited evidence or expert opinion only. 
Men in whom MTVT is suspected at initial presentation, pri-
mary hemiscrotectomy, and en-bloc orchidectomy should be 
performed. In men with suspicious findings discovered dur-
ing surgery, we recommend completing the hydrocelectomy 
as planned and only proceeding thereafter to a hemiscrotec-
tomy if the final histopathology confirms the diagnosis of 
MTVT. This is mainly since most men scheduled for routine 
scrotal surgery such as hydrocelectomy are not consented 
for a hemiscrotectomy and the diagnostic accuracy of intra-
operative frozen section remains ill-defined. For men with an 
incidental diagnosis of MTVT in the hydrocelectomy speci-
men, we recommend timely completion of a hemiscrotec-
tomy because of potential tumor seeding.
Well-differentiated papillary mesothelioma and benign 
multicystic mesothelioma are clearly benign entities that 
require complete resection as definitive therapy; thereafter, 
only follow-up for local relapse is advisable. By contrast, 
malignant MTVT exhibited metastatic spread in one-third 
of cases, suggesting repeated cross-sectional imaging of the 
chest and abdomen is required for staging and follow-up. 
The available data do not support the regular use of adju-
vant treatment. Half of all cases had involved retroperito-
neal LNDs, and only in a proportion, other organs were also 
affected. Despite the use of RPLND, all patients treated with 
lymphadenectomy, who did not receive additional chemo- 
or radiotherapy, progressed. Thus, RPLND as monotherapy 
does not have the potential to cure patients. Only a few men 
received adjuvant chemo- or radiotherapy which does not 
allow any conclusions.
Patients with metastatic disease have a poor prognosis, 
and standard treatment recommendations are not available. 
Given the experience in pleural mesothelioma and the scarce 
data on MTVT, surgical resection within a multimodal treat-
ment approach can be offered; however, the choice of chem-
otherapy and the role of radiotherapy remain unclear. Pleural 
mesothelioma guidelines recommend Platinum, Pemetrexed 
plus minus Bevacizumab (Opitz et al. 2020) and in one case 
Pemetrexed led to complete response. Additionally, Cispl-
atin and Doxorubicin or Adriamycin and Cyclophosphamide 
could be suggested as a few responses have been observed.
Limitations
The published literature only consists of retrospective case 
reports and small case series with a low number of outcome 
events and missing single-patient data, and multivariable 
analysis was therefore not possible. Our search strategy was 
designed and reviewed by both clinicians and librarians, and 
was predefined in a peer-reviewed protocol. However, the 
possibility remains that not all potentially relevant studies 
were identified; this is an additional source of potential bias. 
Larger and more consistent datasets are needed to develop 
prediction models involving several risk factors. Neverthe-
less, the current analysis provides a unique overview of the 
published experience with MTVTs. Due to the absence of 
prospective trials, we recently opened the OrphAn Testis 
Histologies (OATH) to provide more conclusive recom-
mendations regarding clinical course, management, and 
follow-up of these rare entities. We encourage collaborators 
to contribute data regarding patients with rare testis cancer 
histologies (http://bit.ly/OATH-regis try).
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